ArticleScientific reports2025
Development of a liquid overlay-based three-dimensional cell culture panel for drug screening applications.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advantages and research progress of three-dimensional culture systems for lung cancer drug screening (Review).Oncology letters · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
3D cell culture has emerged as a relevant and promising alternative model for improving the preclinical phase of pharmaceutical development. It mimics cell-cell and cell-matrix interactions, as well as drug penetration and toxicity responses. However, there are currently no standardized methods that could lead to highly predictive treatment responses. In this context, the focus of this study was the adaptation of a liquid overlay technique, to generate a large and reproducible panel of six spheroid models, including melanoma, small cell lung cancer, non-small cell lung cancer, ovarian cancer, non-tumorigenic breast tissue and healthy kidney tissue. In this way, four cell concentrations (200 to 10,000 cells per well) with four matrix percentages (0 to 3%) were tested to determine the optimal combination based on their compaction, proliferation and viability. The surface characterization of each model was then assessed using scanning electron microscopy. Afterwards, the cytostatic and cytotoxic responses of these models to three targeted anti-PARP therapies, Olaparib, Rucaparib and Niraparib, were analyzed, revealing their sensitivity. These results demonstrated that our liquid overlay-based technique provides both a large cell culture panel, whatever the tissue type or pathological level, and an automated drug screening process that could lead to highly predictive efficacy results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.